The Effect of Saffron (Crocus sativus) Carotenoids on Hemostasis and Atherosclerosis

Zacharias M Sinakosa1 and George D Geromichalosb
1Aristotelian University of Thessaloniki, Thessaloniki, Greece
2Department of Cell Culture, Molecular Modeling and Drug Design, Symeondion Research Center, Theagenion Cancer Hospital, Thessaloniki, Greece

Corresponding author: George D Geromichalos, Department of Cell Culture, Molecular Modeling and Drug Design, Symeondion Research Center, Theagenion Cancer Hospital, Thessaloniki, Greece, Tel: +302313301111; E-mail: geronchem@yahoo.gr

Rec date: Apr 21, 2016; Acc date: June 28, 2016; Pub date: June 30, 2016

Abstract

In current review is described in short the findings indicating that Crocus sativus exerts antithrombotic and anti-atherosclerosis effect. Summarily, these findings include the documented antioxidant activity of C. sativus on LDL oxidation leading to the initiation of atherosclerosis, its inhibitory effect on the expression of cell adhesion molecules and the adhesion of leucocytes to endothelial cells. Additionally, C. sativus contributes in the inhibition of platelet aggregation, inhibiting coagulation factor Xa and COX-1 (in vitro and in silico studies). All these activities contribute to the inhibition of the progression of atherosclerosis.

Keywords: Saffron; Antithrombotic; Antiplatelet; Atherosclerosis

Mini Review

It is known that a major part of pharmaceutical compounds that we use today are originated from plants. It is indicative that 157 out of 520 formulations approved in the USA between 1983 and 1994, were natural products [1]. According to an interesting the level of success in natural products [1]. According to an interesting the level of success in plant derived drug discovery for clinical use, raises dramatically [2]. Amongst the plants that are under relevant research, especially regarding cardiovascular disease is saffron [3]. The plant was utilized since ancient times (>2000 B.C.), especially at regions of Persia and India. At the same period, it was used in Greece, as observed at some well-known wall paintings at Knossos and Santorini. The evaluation of its healing properties during the Classical period is summarized in the relevant reference of Dioskorides, “saffron is very potent at its medical use” [4]. Nowadays’ research started approximately 40 years ago and peaked during the last decade with a multitude of theses, mainly at experimental level. Lately, some clinical trials have started in depression, Alzheimer’s disease, metabolic syndrome and degenerative eye disease [5-8]. It should be noted that it is difficult to decode the pharmaceutical properties of saffron, since they sometimes refer to its whole extract, and sometimes to its main biological constituents: crocin, crocetin and safranal (Figure 1). Research for the antithrombotic effect of saffron mainly focuses on the arterial part. The first who observed that cardiovascular events were less frequent in a region of Spain, probably due to higher consumption of saffron [9]. This resembles the well-known “French paradox” with wine [10]. One year later, the beneficial effect of crocetin in atherosclerosis in mice [11]. This was expected, since there were not relevant theses and findings in support of such a correlation. The research endeavor to this direction was attempted and continued mainly during the last decade, with remarkable results. The intervention of saffron in this case regards the first stage, the start of the arterial damage, as well as the last stage, the creation of platelet thrombus.
muscle cells which migrate to the inner layer, will gradually participate in the formation of the atheromatous plaque. Potential rupture of the plaque is followed firstly by the adhesion of platelets, afterwards by their aggregation, and eventually by the formation of thrombus. So far, medicine intervenes only in the stage of aggregation with the known inhibitors, the "antiplatelet drugs". An in vitro study noted that the extract of saffron inhibits the aggregation of platelets. This effect with the induced inhibition of the secretion of intracellular Ca²⁺ [20,21].

In silico studies demonstrated that crocetin and picrocrocin have the same binding site with aspirin in cyclooxygenase I (COX-1) (Figure 2). The similar results in an in vitro study. Therefore, it is possible that through this pathway saffron exerts its antiplatelet effect [22,23].

Some interesting findings about the hypolipidemic effects of saffron are presented which attribute these effects to the inhibition of pancreatic lipase by saffron, leading to the malabsorption of cholesterol. Concerning saffron’s activity in the blood clotting mechanism, the relevant observations are limited [19]. An in vitro study noted significant increase of prothrombin time and of partial thromboplastin time in the presence of crocin, as well as the inhibition of Xa factor in silico (Figure 3). Administration of saffron at volunteers, 200 and 400 mg/d for 7 days, did not lead to increase of prothrombin time and of partial thromboplastin time [21,24]. Tsantarliotou et al. in a recent study, observed that administration of crocetin significantly improved the condition of disseminated intravascular coagulation (hematological parameters and kidney fibrosis) in rabbits, after infusion of endotoxin [25].

As a result, the overall antithrombotic effect of saffron, could be attributed to crocetin's inhibitory effect in the development of experimental hyperlipidemic atherosclerosis in quails and rabbits. It should be especially noted that saffron is non-toxic (a study has shown an LD50 value of 20.7 g/Kg) and has no side effects [15,27-30]. As a summary, it is concluded that saffron exerts antithrombotic effect, especially at the arterial part. This effect, observed at the whole extract as well as individual constituents (crocin, crocetin etc.), obviously shows that saffron presents clinical interest, especially in atherosclerosis.

References